Substitutional variants of APO-2 ligand
US6740739B1 · kind B1 · utility
20Cited by
26References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 26, 2000 |
| Grant date | May 25, 2004 |
| Priority date | — |
| Expiry date | Jun 26, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.